AstraZenecom's Dagrid Net DAPA-CKD III study

A new subgroup analysis of AstraZeneta's groundbreaking Dagley Net DAPA-CKD III clinical study shows that, on a standard basis, Dagrid Net can delay renal function deterioration and reduce the risk of cardiovascular or kidney disease death in patients with chronic kidney disease (CKD), regardless of the cause.Chronic kidney disease is a serious disease in which renal function declines, affecting nearly 700 million people worldwide, and many patients are undiagnosed. In the United States, nearly 80 million adults are at high risk of chronic kidney disease. According to 2012 data, the prevalence of chronic kidney disease in China is 10.8%, with nearly 120 million patients. The most common causes of chronic kidney disease include diabetes (38 per cent), hypertension (26 per cent) and ngneer nephritis (16 per cent).Subgroup data showed that compared to placebo, Dagle net had a 37% lower relative risk (RRR) for patients with diabetic nephropathy (absolute risk reduction of 5.8%) and a 25% lower relative risk for patients with chronic kidney disease due to hypertension (ARR s 2.2) %) reduced the relative risk of chronic kidney disease by 57% (ARR - 7.5%), and patients with chronic kidney disease with other or unknown causes decreased their relative risk by 42% (ARR s 5.0%) (RRR interaction p value of 0.53). Similarly, compared to placebos, Dagrid was able to reduce the risk of all-cause death at the secondary endpoint of patients with chronic kidney disease of any cause. (Interactive p-value is 0.55).In the DAPA-CKD III study, it was observed that the safety and tolerance of arriving at gref was consistent with the known safety of the drug.Professor Hiddo L. Heerspink, Executive Committee of DAPA-CKD Clinical Trials, said: "These results are further evidence that Dagley Net has the potential to change the existing standard treatment for a wide range of chronic kidney disease patients with any cause, which will give unlimited hope to hundreds of millions of chronic kidney disease patients worldwide. "The DAPA-CKD study promises to be the first SGLT2 inhibitor to significantly extend the survival of patients with or without type 2 diabetes with chronic kidney disease," said Mene Pangalos, Executive Vice President, Biopharmaceutical Research and Development, Astrain. These newly published study data provide further evidence that Daglyn can bring sustainable and clinically valuable benefits to a wide range of chronic kidney disease patients who urgently need new treatment options to slow their progression. Detailsthe study were officially announced at the 2020 Annual Meeting of the American Society of Nephrology (ASN) Kidney Week.In October 2020, the FDA awarded Dagrid a breakthrough therapy for patients with or without type 2 diabetes. In the same month, the European Medicines Agency (EMA) Committee on Human Pharmaceutical Products (CHMP) recommended approval of Dagrid for heart failure treatment. In addition, in May 2020, Dagrid was approved in the United States to treat adult patients with or without type 2 diabetes with reduced blood failure (HFrEF) adult patients (NYHA II-IV), which reduces the risk of cardiovascular death and hospitalization for heart failure.About Chronic Kidney DiseaseChronic Kidney Disease (CKD) is a serious disease in which the patient's renal function decreases aggressively (marked by a decrease in eGFR or kidney damage or both, and lasts for more than three months). Once a patient enters the most severe stage of CKD, i.e. end-stage kidney disease (ESKD), his or her kidneys are severely damaged, his or her kidney function deteriorates sexually and can only be sustained by dialysis or kidney transplantation, and most patients with chronic kidney disease die of cardiovascular disease before progressing to terminal chronic kidney disease.About DAPA-CKD Study DAPA-CKD is an international multicenter, randomized, double-blind, placebo-controlled clinical study that included 4304 patients with or without type 2 diabetes with stage 2-4 stage albuminuria elevation, assessing the effect of using Dagley net 10 mg/day on the basis of standard treatment. Details of the study, published in August 2020 and published in the New England Journal of Medicine, showed that Dagly net reached the primary compound endpoint compared to placebos, delaying kidney disease in patients with or without type 2 diabetes Functional deterioration (defined as a continuous decline of eGFR ≥50%, progression to end-stage renal disease) or a compound endpoint risk of death due to cardiovascular or kidney disease (p < 0.0001). Daglie net also reached all secondary endpoints, including the first renal complex endpoint event (eGFR continued to decline ≥50%, progressing to death due to end-stage kidney disease or kidney disease), a compound endpoint of cardiovascular death or heart failure hospitalization and a 31% reduction in total cause of death (ARR s 2.1%, p s 0.0035).

about Dagly'sDagle net is the first sodium-glucose co-transport protein-2 (SGLT2) inhibitor of its kind, used to treat adults with type 2 diabetes once a day, can be treated with a single drug, but also on the basis of diet and exercise to treat people with type 2 diabetes with poor blood sugar control, as well as weight loss and the additional benefits of blood pressure reduction and blood pressure reduction. DECLARE-TIMI 58 Cardiovascular Prognostic Studies have shown that the addition of daglycemide to standard treatments compared to placebos can effectively reduce the risk of hospitalization (hHF) or cardiovascular death in adults with type 2 diabetes.Currently, two studies are under way to assess the efficacy of Dagrid net in patients with heart failure, DELIVER (Heart Failure, HFpEF) and DETERMINE (HFrEF and HFpEF). In addition, another ongoing study, DAPA-MI, is aimed at patients with acute heart attacks (MI) or heart attacks that do not combine type 2 diabetes, and is the first to attempt to apply for new adaptations based on a registered randomized controlled trial. Dagrid has a well-developed clinical research program, including 35 completed and ongoing Phase IIb/III trials, which include more than 35,000 patients and have accumulated more than 2.5 million years of experience. (AstraZeneta's official website)